Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Insights into Imaging
Published in: Insights into Imaging 1/2019

Open Access 01-12-2019 | Hepatocellular Carcinoma | Pictorial Review

MRI assessment of hepatocellular carcinoma after locoregional therapy

Authors: Rasha S. Hussein, Wahid Tantawy, Yasser A. Abbas

Published in: Insights into Imaging | Issue 1/2019

Login to get access

Abstract

Liver cirrhosis and hepatocellular carcinoma (HCC) constitute one of the major causes of morbidity, mortality, and high health care costs worldwide. Multiple treatment options are available for HCC depending on the clinical status of the patient, size and location of the tumor, and available techniques and expertise. Locoregional treatment options are multiple. The most challenging part is how to assess the treatment response by different imaging modalities, but our scope will be assessing the response to locoregional therapy for HCC by MRI. This will be addressed by conventional MR methods using LI-RADS v2018 and by functional MR using diffusion-weighted imaging, perfusion, and highlighting the value of the novel intravoxel incoherent motion (IVIM).
Literature
1.
Shaker MK (2016) Epidemiology of HCC in Egypt. Gastroenterol Hepatol 4(3):00097
2.
3.
4.
Chung JC, Naik NK, Lewandowski RJ et al (2010) Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World J Gastroenterol 16(25):3161–3167PubMedPubMedCentralCrossRef
5.
Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB (2010) MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:532–540
6.
Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B (2013) Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. AJR Am J Roentgenol 201:80–96
7.
Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth and spread: key pathologic and imaging aspects. Radiology 272:635–654PubMedPubMedCentralCrossRef
8.
Yu NC, Chaudhari V, Raman SS et al (2011) CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 9:161–167PubMedCrossRef
9.
Qian MY, Yuwei J R, Angus P, Schelleman T, Johnson L, Gow P (2010) Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital. J Gastroenterol Hepatol 25:951–956
10.
Singal A, Volk ML, Waljee A et al (2009) Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 30:37–47PubMedCrossRef
11.
Santi V, Trevisani F, Gramenzi A et al (2010) Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 53:291–297PubMedCrossRef
12.
13.
14.
Chen MS, Li JQ, Zheng Y et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243:321–328PubMedPubMedCentralCrossRef
15.
Livraghi T, Meloni F, Di Stasi M et al (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47:82–89PubMedCrossRef
16.
Chinnaratha MA, Chuang MY, Fraser RJ, Woodman RJ, Wigg AJ (2016) Percutaneous thermal ablation for primary hepatocellular carcinoma: a systematic review and meta-analysis. J Gastroenterol Hepatol 31(2):294–301
17.
Lammer J, Malagari K, Vogl T et al (2010) Precision V investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52PubMedCrossRef
18.
Bammer R, Keeling SL, Augustin M et al (2001) Improved diffusion-weighted single-shot echo-planar imaging (EPI) in stroke using sensitivity encoding (SENSE). Magn Reson Med 46:548–554PubMedCrossRef
19.
Taouli B, Martin AJ, Qayyum A et al (2004) Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: preliminary experience in healthy volunteers. AJR Am J Roentgenol 183:677–680
20.
Rosenkrantz AB, Oei M, Babb JS, Niver BE, Taouli B (2011) Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging 33:128–135
21.
Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622–1635
22.
Baliyan V, Das CJ, Sharma S, Gupta AK (2014) Diffusion-weighted imaging in urinary tract lesions. Clin Radiol 69:773–782PubMedCrossRef
23.
Chandarana H, Taouli B (2010) Diffusion and perfusion imaging of the liver. Eur J Radiol 76:348–358PubMedCrossRef
24.
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef
25.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
26.
Suzuki C, Jacobsson H, Hatschek T et al (2008) Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28:329–344PubMedCrossRef
27.
Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711PubMedCrossRef
28.
Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference—European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef
29.
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef
30.
Shim JH, Lee HC, Kim SO et al (2012) Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 262:708–718PubMedCrossRef
31.
Kim BK, Kim KA, Park JY et al (2013) Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 49:826–834PubMedCrossRef
32.
Gillmore R, Stuart S, Kirkwood A et al (2011) EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 55:1309–1316PubMedCrossRef
33.
Lencioni R, Llovet JM (2010) Modified RECIST(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60PubMedCrossRef
34.
35.
Kielar A, Fowler KJ, Lewis S et al (2018) Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 43:218–230
36.
Dromain C, de Baere T, Elias D et al (2002) Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 223:255–262PubMedCrossRef
37.
Winters SD, Jackson S, Armstrong GA, Birchall IW, Lee KH, Low G (2012) Value of subtraction MRI in assessing treatment response following image-guided loco-regional therapies for hepatocellular carcinoma. Clin Radiol 67:649–655
38.
Hoffmann R, Rempp H, Schraml C et al (2015) Diffusion-weighted imaging during MR-guided radiofrequency ablation of hepatic malignancies: analysis of immediate pre- and post-ablative diffusion characteristics. Acta Radiol 56(8):908–916
39.
Jiang T, Zhu AX, Sahani DV (2013) Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol 58:169–177
40.
Sainani NI, Gervais DA, Mueller PR, Arellano RS (2013) Imaging after percutaneous radiofrequency ablation of hepatic tumors: part 1, normal findings. AJR Am J Roentgenol 200:184–193
41.
Kim YS, Rhim H, Lim HK (2009) Imaging after radiofrequency ablation of hepatic tumors. Semin Ultrasound CT MR 30:49–66
42.
Kim SK, Lim HK, Kim YH et al (2003) Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. Radiographics 23:107–121PubMedCrossRef
43.
Kierans AS, Elazzazi M, Braga L et al (2010) Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response. AJR Am J Roentgenol 194:523–529
44.
Park MH, Rhim H, Kim YS, Choi D, Lim HK, Lee WJ (2008) Spectrum of CT findings after radiofrequency ablation of hepatic tumors. Radiographics 28:379–390
45.
Park Y, Choi D, Lim HK et al (2008) Growth rate of new hepatocellular carcinoma after percutaneous radiofrequency ablation: evaluation with multiphase CT. AJR Am J Roentgenol 191:215–220
46.
Agnello F, Salvaggio G, Cabibbo G et al (2013) Imaging in treated hepatocellular carcinoma. World J Hepatol 5(8):417–424
47.
Di Stasi M, Ruscarini L, Livraghi T et al (1997) Percutaneous ethanol injection therapy in the treatment of hepatocellular carcinoma. A multicenter survey of evaluation practices and complication rate. Scand J Gastroenterol 32:1168–1173
48.
Vossen JA, Buijs M, Kamel IR (2006) Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol 9:125–132PubMedCrossRef
49.
Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 193:1044–1052
50.
Hunt SJ, Yu W, Weintraub J, Prince MR, Kothary N (2009) Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 20:30–38
51.
Khankan AA, Murakami T, Onishi H et al (2008) Hepatocellular carcinoma treated with radio frequency ablation: an early evaluation with magnetic resonance imaging. J Magn Reson Imaging 27:546–551PubMedCrossRef
52.
53.
Lee AJ, Gomes AS, Liu DM, Kee ST, Loh CT, McWilliams JP (2012) The road less traveled: importance of the lesser branches of the celiac axis in liver embolotherapy. Radiographics 32:1121–1132
54.
Riaz A, Kulik L, Lewandowski RJ et al (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49:1185–1193PubMedCrossRef
55.
Ibrahim SM, Nikolaidis P, Miller FH et al (2009) Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 34:566–581PubMedCrossRef
56.
Keppke AL, Salem R, Reddy D et al (2007) Imaging of hepatocellular carcinoma after treatment with yttrium- 90 microspheres. AJR Am J Roentgenol 188:768–775
57.
Alonzi R, Hoskin P (2006) Functional imaging in clinical oncology: magnetic resonance imaging– and computerised tomography–based techniques. Clin Oncol (R Coll Radiol) 18:555–570CrossRef
58.
59.
60.
Koh DM, Brown G, Riddell AM et al (2008) Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol 18:903–910PubMedCrossRef
61.
van den Bos IC, Hussain SM, Krestin GP, Wielopolski PA (2008) Liver imaging at 3.0T: diffusion-induced black-blood echo-planar imaging with large anatomic volumetric coverage as an alternative for specific absorption rate-intensive echo-train spin-echo sequences: feasibility study. Radiology 248:264–271PubMedCrossRef
62.
Coenegrachts K, Delanote J, Ter Beek L et al (2007) Improved focal liver lesion detection: comparison of single shot diffusion-weighted echoplanar and single-shot T2 weighted turbo spin echo techniques. Br J Radiol 80:524–531PubMedCrossRef
63.
Low RN, Gurney J (2007) Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhancedand gadolinium-enhanced MRI. J Magn Reson Imaging 25:848–858
64.
Hardie AD, Naik M, Hecht EM et al (2010) Diagnosis of liver metastases: value of diffusion- weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol 20:1431–1441PubMedCrossRef
65.
Elbarbary AA, Saleh Elahwal HM, Elashwah ME (2015) Role of diffusion-weighted magnetic resonance imaging in evaluation of hepatic focal lesions. Egypt J Radiol Nucl Med 46:325–334CrossRef
66.
Piana G, Trinquart L, Meskine N, Barrau V, Beers BV, Vilgrain V (2011) New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol 55:126–132
67.
Vandecaveye V, De Keyzer F, Verslype C et al (2009) Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 19:2456–2466PubMedCrossRef
68.
Catalano OA, Choy G, Zhu A et al (2010) Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 254:154–162PubMedCrossRef
69.
Wagner M, Doblas S, Daire JL et al (2012) Diffusion-weighted MR imaging for the regional characterization of liver tumors. Radiology 264:464–472PubMedCrossRef
70.
Gluskin JS, Chegai F, Monti S, Squillaci E, Mannelli L (2016) Hepatocellular carcinoma and diffusion-weighted MRI: detection and evaluation of treatment response. J Cancer 7(11):1565–1570
71.
Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF (2009) Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 250:466–473
72.
Kamel IR, Bluemke DA, Ramsey D et al (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 181:708–710
73.
Chapiro J, Wood LD, Lin M et al (2014) Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology 273:746–758PubMedPubMedCentralCrossRef
74.
Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR (2011) Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology 260:752–761
75.
Sahin H, Harman M, Cinar C, Bozkaya H, Parildar M, Elmas N (2012) Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging. J Vasc Interv Radiol 23:241–247
76.
Yuan Z, Li WT, Ye XD, Peng WJ, Xiao XS (2014) Utility of diffusion-weighted imaging to assess hepatocellular carcinoma viability following transarterial chemoembolization. Oncol Lett 8:831–836
77.
Kokabi N, Camacho JC, Xing M et al (2014) Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following Yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. Abdom Imaging 39:969–978PubMedCrossRef
78.
Rhee TK, Naik NK, Deng J et al (2008) Tumor response after Yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19:1180–1186PubMedCrossRef
79.
Park HJ, Kim SH, Jang KM, Lee SJ, Park MJ, Choi D (2013) Differentiating hepatic abscess from malignant mimickers: value of diffusion-weighted imaging with an emphasis on the periphery of the lesion. J Magn Reson Imaging 38:1333–1341
80.
Yu JI, Park HC, Lim DH et al (2014) The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 89:814–821PubMedCrossRef
81.
Schraml C, Schwenzer NF, Martirosian P et al (2009) Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 193:W301–W307
82.
83.
Schraml C, Schwenzer NF, Clasen S et al (2009) Navigator respiratory-triggered diffusion-weighted imaging in the follow-up after hepatic radiofrequency ablation-initial results. J Magn Reson Imaging 29:1308–1316PubMedCrossRef
84.
Yuan Z, Ye XD, Dong S et al (2010) Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol 75:e9–e14PubMedCrossRef
85.
Shao H, Ni Y, Zhang J, et al (2013) Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors. PLoS One 8:e82649
86.
Kim SY, Lee SS, Byun JH et al (2010) Malignant hepatic tumors: short-term reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. Radiology 255:815–823PubMedCrossRef
87.
Kim SY, Lee SS, Park B et al (2012) Reproducibility of measurement of apparent diffusion coefficients of malignant hepatic tumors: effect of DWI techniques and calculation methods. J Magn Reson Imaging 36:1131–1138PubMedCrossRef
88.
Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125PubMedPubMedCentralCrossRef
89.
Kokabi N, Camacho JC, Xing M, Edalat F, Mittal PK, Kim HS (2015) Immediate post-doxorubicin drug-eluting beads chemoembolization MR apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: a pilot study. J Magn Reson Imaging 42(4):981–989
90.
Kokabi N, Ludwig JM, Camacho JC, Xing M, Mittal PK, Kim HS (2015) Baseline and early MR apparent diffusion coefficient quantification as a predictor of response of unresectable hepatocellular carcinoma to doxorubicin drug-eluting bead chemoembolization. J Vasc Interv Radiol 26(12):1777–1786
91.
Dong S, Ye XD, Yuan Z, Xu LC, Xiao XS (2012) Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization. Eur J Radiol 81:472–477
92.
Goshima S, Kanematsu M, Kondo H et al (2008) Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 27:834–839PubMedCrossRef
93.
Hagiwara M, Rusinek H, Lee VS et al (2008) Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging—initial experience. Radiology 246:926–934PubMedCrossRef
94.
Abdullah SS, Pialat JB, Wiart M et al (2008) Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI. J Magn Reson Imaging 28:390–395PubMedCrossRef
95.
Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B (2010) Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 31:589–600
96.
Jarnagin WR, Schwartz LH, Gultekin DH et al (2009) Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 20:1589–1595PubMedPubMedCentralCrossRef
97.
Yopp AC, Schwartz LH, Kemeny N et al (2011) Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 18:2192–2199PubMedPubMedCentralCrossRef
98.
Wang D, Gaba RC, Jin B et al (2011) Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Acad Radiol 18:828–836PubMedPubMedCentralCrossRef
99.
Taouli B, Johnson RS, Hajdu C et al (2013) Hepatocellular carcinoma: perfusion quantification with 3D perfusion-weighted MR imaging. AJR Am J Roentgenol 201(4):795–800
100.
101.
102.
Padhani AR (2002) Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 16:407–422PubMedCrossRef
103.
Wang J, Chen LT, Tsang YM, Liu TW, Shih TT (2004) Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol 183:713–719
104.
Miyazaki K, Collins DJ, Walker-Samuel S et al (2008) Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 18:1414–1421PubMedCrossRef
105.
Sahani DV, Holalkere NS, Mueller PR, Zhu AX (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue—initial experience. Radiology 243:736–743PubMedCrossRef
106.
Woo S, Lee JM, Yoon JH, Joo I, Han JK, Choi BI (2014) Diffusion-weighted imaging of hepatocellular carcinoma. Radiology 270:758–767
107.
Woo S, Lee JM, Yoon JH, Joo I, Han JK, Choi BI (2014) Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma: correlation with enhancement degree and histologic grade. Radiology 270:758–767
108.
Mürtz P, Penner A, Pfeiffer A et al (2016) Intravoxel incoherent motion model–based analysis of diffusion-weighted magnetic resonance imaging with 3 b-values for response assessment in locoregional therapy of hepatocellular carcinoma. Onco Targets Ther 9:6425–6433PubMedPubMedCentralCrossRef
109.
Granata V, Fusco R, Catalano O et al (2016) Intravoxel incoherent motion (IVIM) in diffusion-weighted imaging (DWI) for hepatocellular carcinoma: correlation with histologic grade. Oncotarget 48:79357–79364
Metadata
Title
MRI assessment of hepatocellular carcinoma after locoregional therapy
Authors
Rasha S. Hussein
Wahid Tantawy
Yasser A. Abbas
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Insights into Imaging / Issue 1/2019
Electronic ISSN: 1869-4101
DOI
https://doi.org/10.1186/s13244-019-0690-1

Other articles of this Issue 1/2019

Insights into Imaging 1/2019 Go to the issue

Original Article

Clinical evaluation of left ventricular function and morphology using an accelerated k-t sensitivity encoding method in cardiovascular magnetic resonance

Educational Review

Cross-sectional imaging of acute gynaecologic disorders: CT and MRI findings with differential diagnosis—part I: corpus luteum and haemorrhagic ovarian cysts, genital causes of haemoperitoneum and adnexal torsion

Educational Review

Primary myelofibrosis: spectrum of imaging features and disease-related complications

Original Article

Can imaging be the new yardstick for diagnosing peripheral neuropathy?—a comparison between high resolution ultrasound and MR neurography with an approach to diagnosis

Original Article

Trends in scientific research in Insights into Imaging: a bibliometric review

Educational Review

Imaging of shoulder arthroplasties and their complications: a pictorial review